290 related articles for article (PubMed ID: 17520565)
1. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Cozzolino M; Brancaccio D
Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
[TBL] [Abstract][Full Text] [Related]
2. Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
Cozzolino M; Brancaccio D
Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):29-34. PubMed ID: 18221100
[TBL] [Abstract][Full Text] [Related]
3. Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
Cozzolino M; Brancaccio D
Expert Opin Emerg Drugs; 2007 Sep; 12(3):341-3. PubMed ID: 17874964
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for hyperphosphatemia.
Bellinghieri G; Santoro D; Savica V
Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
[TBL] [Abstract][Full Text] [Related]
5. The clinical management of hyperphosphatemia.
Ritz E
J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
[TBL] [Abstract][Full Text] [Related]
6. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Mohammed I; Hutchison AJ
J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
[TBL] [Abstract][Full Text] [Related]
7. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphatemia and phosphate binders.
Schucker JJ; Ward KE
Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
[TBL] [Abstract][Full Text] [Related]
9. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
10. Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
Cozzolino M; Galassi A; Pasho S; Fallabrino G; Gallieni M; Brancaccio D
Contrib Nephrol; 2008; 161():234-239. PubMed ID: 18451682
[TBL] [Abstract][Full Text] [Related]
11. Lanthanum carbonate as a first-line phosphate binder: the "cons".
Drüeke TB
Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
[TBL] [Abstract][Full Text] [Related]
13. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of the non-calcium phosphate binder sevelamer.
Nikolov IG; Joki N; Maizel J; Lacour B; Drüeke TB; Massy ZA
Kidney Int Suppl; 2006 Dec; (105):S16-23. PubMed ID: 17136111
[TBL] [Abstract][Full Text] [Related]
15. Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Savica V; Calò LA; Monardo P; Santoro D; Bellinghieri G
Nephrol Dial Transplant; 2006 Aug; 21(8):2065-8. PubMed ID: 16766546
[No Abstract] [Full Text] [Related]
16. Safety of new phosphate binders for chronic renal failure.
Loghman-Adham M
Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
[TBL] [Abstract][Full Text] [Related]
17. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
Senatore M; Coppolino G; Papalia T; Greco R; Lofaro D; Bonofiglio R
Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1352-4. PubMed ID: 22195373
[No Abstract] [Full Text] [Related]
18. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
Nolan CR; Qunibi WY
Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
20. Phosphate binders in CKD: chalking out the differences.
Rees L; Shroff RC
Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]